Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunoregulation of Dendritic Cell Subsets by Inhibitory Receptors in Urothelial Cancer.
Chevalier MF, Bohner P, Pieraerts C, Lhermitte B, Gourmaud J, Nobile A, Rotman S, Cesson V, Martin V, Legris AS, Dartiguenave F, Gharbi D, De Leval L, Speiser DE, Nardelli-Haefliger D, Jichlinski P, Derré L. Chevalier MF, et al. Among authors: dartiguenave f. Eur Urol. 2017 Jun;71(6):854-857. doi: 10.1016/j.eururo.2016.10.009. Epub 2016 Oct 27. Eur Urol. 2017. PMID: 28277277
Intramuscular Immunization Induces Antigen-specific Antibodies in Urine.
Derré L, Lucca I, Cesson V, Valerio M, Cerantola Y, Burruni R, Fritschi U, Gharbi D, Bobst M, Legris AS, Dartiguenave F, Jichlinski P, Nardelli-Haefliger D. Derré L, et al. Among authors: dartiguenave f. Eur Urol Focus. 2020 Mar 15;6(2):280-283. doi: 10.1016/j.euf.2018.09.003. Epub 2018 Sep 13. Eur Urol Focus. 2020. PMID: 30219710
Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer.
Mastelic-Gavillet B, Sarivalasis A, Lozano LE, Wyss T, Inoges S, de Vries IJM, Dartiguenave F, Jichlinski P, Derrè L, Coukos G, Melero I, Harari A, Romero P, Viganó S, Kandalaft LE. Mastelic-Gavillet B, et al. Among authors: dartiguenave f. Eur J Cancer. 2020 Aug;135:173-182. doi: 10.1016/j.ejca.2020.04.036. Epub 2020 Jun 23. Eur J Cancer. 2020. PMID: 32590296 Free article.
Siglec-6 as a New Potential Immune Checkpoint for Bladder Cancer Patients.
Benmerzoug S, Chevalier MF, Verardo M, Nguyen S, Cesson V, Schneider AK, Dartiguenave F, Rodrigues-Dias SC, Lucca I, Jichlinski P, Roth B, Nardelli-Haefliger D, Derré L. Benmerzoug S, et al. Among authors: dartiguenave f. Eur Urol Focus. 2022 May;8(3):748-751. doi: 10.1016/j.euf.2021.06.001. Epub 2021 Jun 17. Eur Urol Focus. 2022. PMID: 34147404 Free article.
Siglec-7 May Limit Natural Killer Cell-mediated Antitumor responses in Bladder Cancer Patients.
Benmerzoug S, Chevalier MF, Villier L, Nguyen S, Cesson V, Schneider AK, Dartiguenave F, Rodrigues-Dias SC, Lucca I, Jichlinski P, Roth B, Nardelli-Haefliger D, Derré L. Benmerzoug S, et al. Among authors: dartiguenave f. Eur Urol Open Sci. 2021 Nov 18;34:79-82. doi: 10.1016/j.euros.2021.10.001. eCollection 2021 Dec. Eur Urol Open Sci. 2021. PMID: 34825225 Free PMC article.
Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
Derré L, Cesson V, Lucca I, Cerantola Y, Valerio M, Fritschi U, Vlamopoulos Y, Burruni R, Legris AS, Dartiguenave F, Gharbi D, Martin V, Vaucher L, Speiser DE, Romero P, Jichlinski P, Nardelli-Haefliger D. Derré L, et al. Among authors: dartiguenave f. Clin Cancer Res. 2017 Feb 1;23(3):717-725. doi: 10.1158/1078-0432.CCR-16-1189. Epub 2016 Aug 12. Clin Cancer Res. 2017. PMID: 27521445 Clinical Trial.
ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence.
Chevalier MF, Trabanelli S, Racle J, Salomé B, Cesson V, Gharbi D, Bohner P, Domingos-Pereira S, Dartiguenave F, Fritschi AS, Speiser DE, Rentsch CA, Gfeller D, Jichlinski P, Nardelli-Haefliger D, Jandus C, Derré L. Chevalier MF, et al. Among authors: dartiguenave f. J Clin Invest. 2017 Aug 1;127(8):2916-2929. doi: 10.1172/JCI89717. Epub 2017 Jun 26. J Clin Invest. 2017. PMID: 28650339 Free PMC article.
Double Positive CD4+CD8+ T Cells Are Enriched in Urological Cancers and Favor T Helper-2 Polarization.
Bohner P, Chevalier MF, Cesson V, Rodrigues-Dias SC, Dartiguenave F, Burruni R, Tawadros T, Valerio M, Lucca I, Nardelli-Haefliger D, Jichlinski P, Derré L. Bohner P, et al. Among authors: dartiguenave f. Front Immunol. 2019 Mar 29;10:622. doi: 10.3389/fimmu.2019.00622. eCollection 2019. Front Immunol. 2019. PMID: 30984190 Free PMC article. Clinical Trial.
Vδ2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments.
Nguyen S, Chevalier MF, Benmerzoug S, Cesson V, Schneider AK, Rodrigues-Dias SC, Dartiguenave F, Lucca I, Jichlinski P, Roth B, Nardelli-Haefliger D, Derré L. Nguyen S, et al. Among authors: dartiguenave f. J Immunother Cancer. 2022 Aug;10(8):e004880. doi: 10.1136/jitc-2022-004880. J Immunother Cancer. 2022. PMID: 36002184 Free PMC article.
15 results